Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
Type
Private
HQ
Milton, GB
Founded
2015
Replimune was founded in 2015 and is headquartered in Milton, GB
Report incorrect company information

Replimune Office Locations

Replimune has offices in Milton and Woburn
Milton, GB (HQ)
69 Park Dr
Woburn, US
18 Commerce Way
Show all (2)
Report incorrect company information

Replimune Financials and Metrics

Summary Metrics

Founding Date

2015

Total Funding

$30 m

Latest funding size

$30 m

Time since last funding

3 years ago

Investors

Replimune's latest funding round in September 2015 was reported to be $30 m. In total, Replimune has raised $30 m

Replimune Financials

GBP

Net income (FY, 2017)

(3.3 m)

EBITDA (FY, 2017)

(4.3 m)

EBIT (FY, 2017)

(4.4 m)

Cash (31-Mar-2017)

15.9 m
GBPFY, 2016FY, 2017

EBITDA

(671.3 k)(4.3 m)

EBIT

(689.8 k)(4.4 m)

Pre tax profit

(679.4 k)(4.4 m)

Income tax expense

201 k1.1 m
GBPFY, 2016FY, 2017

Cash

9.7 m15.9 m

Current Assets

10.6 m20.3 m

PP&E

115.6 k202.4 k

Total Assets

10.8 m20.5 m
GBPFY, 2016FY, 2017

Net Income

(478.4 k)(3.3 m)

Cash From Operating Activities

(1.4 m)(6 m)

Cash From Financing Activities

11 m12.3 m

Net Change in Cash

9.4 m6.1 m
GBPY, 2017

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information